Compare · LLY vs RNA
LLY vs RNA
Side-by-side comparison of Eli Lilly and Company (LLY) and Atrium Therapeutics Inc. (RNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and RNA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.14T, about 8661.4x RNA ($131.4M).
- Over the past year, LLY is up 53.5% and RNA is down 84.3% - LLY leads by 137.8 points.
- LLY has been more active in the news (25 items in the past 4 weeks vs 12 for RNA).
- Both have 25 recent analyst ratings on file.
- Company
- Eli Lilly and Company
- Atrium Therapeutics Inc.
- Price
- $1257.32+0.45%
- $7.68-1.60%
- Market cap
- $1.14T
- $131.4M
- 1M return
- +9.10%
- -19.49%
- 1Y return
- +53.50%
- -84.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 25
- 12
- Recent ratings
- 25
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Atrium Therapeutics Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Latest RNA
- Amendment: SEC Form 8-K/A filed by Atrium Therapeutics Inc.
- SEC Form 8-K filed by Atrium Therapeutics Inc.
- Atrium Therapeutics Announces $50 Million Private Placement
- Chief Scientific Officer Younis Husam covered exercise/tax liability with 11,216 shares, decreasing direct ownership by 21% to 41,441 units (SEC Form 4) to cover taxes
- Chief Medical Officer Hughes Steven George covered exercise/tax liability with 21,459 shares, decreasing direct ownership by 29% to 51,638 units (SEC Form 4) to satisfy withholding tax
- Director Boyce Sarah covered exercise/tax liability with 126,418 shares, decreasing direct ownership by 48% to 138,668 units (SEC Form 4) (withholding obligation)
- Director Flanagan W. Michael covered exercise/tax liability with 22,812 shares, decreasing direct ownership by 42% to 31,974 units (SEC Form 4) to satisfy withholding tax
- Officer Kenney Stephanie covered exercise/tax liability with 2,375 shares, decreasing direct ownership by 7% to 33,085 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Winslow Brendan R. covered exercise/tax liability with 6,742 shares, decreasing direct ownership by 15% to 36,859 units (SEC Form 4) (for withholding tax)
- Officer Gallagher Kathleen P. covered exercise/tax liability with 11,632 shares, decreasing direct ownership by 9% to 119,729 units (SEC Form 4) (for tax liability)